Final Report of a Trial of Intensive versus Standard Blood-Pressure Control.
null nullCora Elizabeth LewisLawrence J FineSrinivasan BeddhuAlfred K CheungWilliam C CushmanJeffrey A CutlerGregory W EvansKaren C JohnsonDalane W KitzmanSuzanne OparilMahboob RahmanDavid M ReboussinMichael V RoccoKaycee M SinkJoni K SnyderPaul K WheltonJeff D WilliamsonJackson T WrightWalter T AmbrosiusPublished in: The New England journal of medicine (2021)
Among patients who were at increased cardiovascular risk, targeting a systolic blood pressure of less than 120 mm Hg resulted in lower rates of major adverse cardiovascular events and lower all-cause mortality than targeting a systolic blood pressure of less than 140 mm Hg, both during receipt of the randomly assigned therapy and after the trial. Rates of some adverse events were higher in the intensive-treatment group. (Funded by the National Institutes of Health; SPRINT ClinicalTrials.gov number, NCT01206062.).
Keyphrases
- blood pressure
- cardiovascular events
- hypertensive patients
- heart rate
- study protocol
- phase iii
- coronary artery disease
- clinical trial
- healthcare
- cancer therapy
- public health
- cardiovascular disease
- phase ii
- mental health
- fluorescent probe
- left ventricular
- stem cells
- blood glucose
- living cells
- drug delivery
- randomized controlled trial
- high intensity
- replacement therapy
- resistance training
- bone marrow
- mesenchymal stem cells
- social media
- health promotion
- insulin resistance
- adverse drug